Free Trial

Federated Hermes Inc. Grows Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

4D Molecular Therapeutics logo with Medical background

Key Points

  • Federated Hermes Inc. significantly increased its stake in 4D Molecular Therapeutics by 33,131.8%, owning 1,250,181 shares worth approximately $4.04 million as of its latest SEC filing.
  • 4D Molecular Therapeutics reported an EPS of ($0.86) for the quarter, which was below analysts' expectation of ($0.84), highlighting a negative return on equity of 33.26%.
  • Despite mixed performance, analyst ratings indicate a consensus rating of "Moderate Buy" with an average price target of $29.56, despite one "sell" rating present.
  • Want stock alerts on 4D Molecular Therapeutics? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Federated Hermes Inc. increased its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 33,131.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,250,181 shares of the company's stock after purchasing an additional 1,246,419 shares during the quarter. Federated Hermes Inc. owned approximately 2.70% of 4D Molecular Therapeutics worth $4,038,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Y Intercept Hong Kong Ltd acquired a new position in shares of 4D Molecular Therapeutics in the 1st quarter worth approximately $41,000. KLP Kapitalforvaltning AS purchased a new stake in shares of 4D Molecular Therapeutics in the fourth quarter valued at about $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in 4D Molecular Therapeutics during the fourth quarter worth about $50,000. Velan Capital Investment Management LP purchased a new stake in 4D Molecular Therapeutics during the fourth quarter worth about $56,000. Finally, Virtus ETF Advisers LLC lifted its holdings in shares of 4D Molecular Therapeutics by 173.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,333 shares of the company's stock valued at $58,000 after purchasing an additional 6,560 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Stock Up 1.5%

NASDAQ:FDMT traded up $0.09 during trading hours on Thursday, hitting $5.82. 439,291 shares of the company traded hands, compared to its average volume of 878,028. 4D Molecular Therapeutics, Inc. has a one year low of $2.23 and a one year high of $17.41. The company has a market cap of $269.46 million, a PE ratio of -1.84 and a beta of 2.83. The firm's 50-day simple moving average is $4.34 and its 200-day simple moving average is $4.06.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. As a group, equities research analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on FDMT. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Tuesday, July 29th. Chardan Capital reiterated a "buy" rating and set a $25.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, August 1st. The Goldman Sachs Group reduced their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, Barclays cut their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $29.56.

Check Out Our Latest Analysis on 4D Molecular Therapeutics

4D Molecular Therapeutics Profile

(Free Report)

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

Featured Stories

Institutional Ownership by Quarter for 4D Molecular Therapeutics (NASDAQ:FDMT)

Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?

Before you consider 4D Molecular Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.

While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines